- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff White: Collaboration Is Key to Combatting Opioid Epidemic
Jeff White, PharmD, MS, staff vice president, Anthem, discusses what role Anthem has in addressing the opioid epidemic, as well as how important collaboration with other stakeholders is for addressing the epidemic.
Jeff White, PharmD, MS, staff vice president, Anthem, discusses what role Anthem has in addressing the opioid epidemic, as well as how important collaboration with other stakeholders is for addressing the epidemic.
TranscriptAs a payer, what role do you have in addressing the opioid epidemic?
Anthem has taken a national leadership role in addressing the opioid abuse epidemic. We set out a goal of reducing opioid use by 30% by 2019 from its peak in 2012. We’ve achieved that goal 2 years early. In fact, we’ve achieved over a 40% reduction in opioid use since the peak in 2012. So, Anthem has an important role in helping to address the opioid abuse epidemic.
How important is it to collaborate with other stakeholders in order to ensure success with these different initiatives?
This epidemic is so large and vast and complicated, it’s going to take effort from a number of different stakeholders to help address this epidemic. For example, the government, regulatory agencies, health plans such as Anthem, PBMs [pharmacy benefit managers], physicians, educating patients, are all necessary to help address the opioid abuse epidemic.
Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak
February 13th 2025In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
